Please assess the completion status of the following clinical trial:

Trial Title: OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* FEV1/FVC ratio (post-bronchodilator) ≤70%~* FEV1 (post-bronchodilator) ≤50% of predicted~* Current smoker or ex-smoker~* Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline~* Availability of chest x-ray dated a maximum of 6 months prior to study baseline or a willingness to have a chest x-ray performed at baseline~Main Exclusion Criteria:~* COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline~* Lower respiratory tract infection not resolved 4 weeks prior to baseline~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Need for long-term oxygen therapy defined as ≥16 hours/day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).